Table II.

Post-immunization responses to HLA-A2-restricted peptides

ProteinPeptideIC50 (nM)aVaccine-Induced CD8+ T Cell Response
% Patients with responseb (n = 22)Response levelc
MAGE-3271–279FLWGPRALV61.01410.6, 89.2, −17.6d,e
MAGE-3188–198IMPKAGLLIIV20.058.2
MAGE-3159–169QLVFGIELMEV7.9911.8, 5.8
Melan-A/MART-131–39GILTVILGV4.658.3
Melan-A/MART-156–64ALMDKSLHV17.2945.5,f 12.7
Melan-A/MART-127–35AAGIGILTV1063.8511.7f
gp100178–186MLGTHTMEV14.3513.0
gp10013–21AVIGALLAV17.9569.5f
gp100250–259YLAEADLSYT45.50
gp100619–627RLMKQDFSV46.30
gp100177–186AMLGTHTMEV51.95−5.5e
gp100585–593IMPGQEAGL64.9146.1, 8.4, 10.7
gp10011–19HLAVIGALL106.457.7
gp100606–614LMAVVLASL111.10
gp100232–241FLRNQPLTFA138.95−10.3e
gp100570–578SLADTNSLA454.6514.8
Tyrosinase9-17LLWSFQTSA15.20
Tyrosinase8–17BLLWSFQTSA19.2911.5, −6.3e
Tyrosinase214–222FLLRWEQEI25.6522.4
Tyrosinase477–486WLLGAAMVGA32.10
Tyrosinase2–10LLAVLYCLL33.30
Tyrosinase490–499ALLAGLVSLL56.40
Tyrosinase482–490AMVGAVLTA75.596.8, 17.1
Tyrosinase490–498ALLAGLVSL76.3521.8
Tyrosinase487–495VLTALLAGL82.099.3, 13.4
Tyrosinase491–499LLAGLVSLL95.20
Tyrosinase473–481RIWSWLLGA100.00
Tyrosinase207–215FLPWHRLFL112.30
Tyrosinase207–216FLPWHRLFLL204.90
MC1R99–197LLLEAGALV6.70
MC1R251–259FLCWGPFFL38.5923.4f
MC1R291–299gSVMDPLIYA83.30
MC1R9–17RLLGSLNST166.70
MC1R291–299AIIDPLIYA238.1522.2
MC1R79–87CLALSDLLV357.1513.7
MC1R291–299gSIIDPLIYA454.60
TRP-2431–439NMVPFFPPV3.90
TRP-2185–193FVWLHYYSV15.20
TRP-2455–463YAIDLPVSV15.6937.1f , 36.1
TRP-2288–296SLDDYNHLV26.30
TRP-2476–484VMGTLVALV27.80
TRP-2180–188SVYDFFVWL35.7916.6, −6.4e
TRP-2475–483VVMGTLVAL66.70
TRP-2156–164YVITTQHWL104.20
TRP-2367–376SLHNLVHSFL263.2915.4, −19.8e
CSP334–342YLKKIKNSLNTh0
  • a IC50 is defined as the concentration of peptide required to inhibit 50% of the binding of a test peptide to purified HLA-A*0201 molecules.

  • b The percent of patients out of those tested, who recognized the peptide.

  • c The actual CD8+ T cell responses, i.e. the number of IFN-γ-secreting CD8+ T cells/500,000 PBL. These were calculated by subtracting the number of IFN-γ-secreting cells in wells treated with anti-CD8 from wells without Abs, both in the presence of the same peptide. Mean standard deviation was ±0.95.

  • d More than one value indicates multiple patient responses.

  • e −, Response decreased after vaccine immunization.

  • f Response increased further by vaccine immunization.

  • g Analog (three amino acids have been changed from the original sequence).

  • h NT, Not tested.